- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07948720
Dexmedetomidine as an Adjuvant to Bupivacaine in Fascia Iliaca Block for Femoral Fracture Surgery Under General Anesthesia: A Dose-Finding Study (FIB-DEX)
Dexmedetomidine Added to Bupivacaine in Fascia Iliaca Block Combined With General Anesthesia for Femoral Fracture Surgery: A Dose-Finding Randomized Double-Blind Study
### Brief Summary
Femoral fractures can cause severe pain during and after surgery. Although fascia iliaca block is commonly used to relieve pain in patients undergoing femoral fracture surgery, the duration of pain relief may be limited.
Dexmedetomidine is a medication that may prolong the pain-relieving effect of local anesthetics such as bupivacaine. However, the most appropriate dose of dexmedetomidine for this type of nerve block is not yet clearly established.
This study aims to determine the lowest effective dose of dexmedetomidine when added to bupivacaine for ultrasound-guided fascia iliaca block in patients undergoing femoral fracture surgery under general anesthesia.
The study includes 90 adult patients, aged 18-75 years, who are scheduled for femoral fracture surgery. Participants will be randomly assigned to one of three groups, with 30 patients in each group. All patients will receive general anesthesia and an ultrasound-guided fascia iliaca block containing 30 mL of 0.25% bupivacaine, combined with one of the following doses of dexmedetomidine:
- Group A: 0.5 micrograms/kg.
- Group B: 0.75 micrograms/kg.
- Group C: 1 microgram/kg.
Neither the patients nor the doctors assessing the study outcomes will know which dose has been administered.
Pain levels will be assessed during the first 24 hours after surgery using a numerical pain scale. The study will also measure the time until patients first require additional pain medication and the total amount of pain medication used.
Other assessments will include leg muscle strength, level of sedation, heart rate, blood pressure, and any possible side effects or complications.
The main purpose of this study is to identify the lowest dose of dexmedetomidine that provides effective postoperative pain relief while minimizing unwanted effects, helping improve pain management and recovery after femoral fracture surgery.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Alaa Taha, MD
- 전화번호: +201276143115
- 이메일: Alaa.Taha@kasralainy.edu.eg
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Age between 18-75 years. both sexes. American Society of Anesthesiologists (ASA) physical status I-III Scheduled for femoral fracture surgery
Exclusion Criteria:
Allergy to study drugs. Heart block type II. Pre-existing neurologic or psychiatric disease. Severe hepatic or renal impairment. Infection at injection site.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: dexmedetomidine 0.5
Name: Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia |
Intervention 1 - Group dexmeditomidine 0.5 Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. ---
다른 이름들:
|
|
활성 비교기: dexmedetomidine 0.75
Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
|
활성 비교기: dexmedetomidine 1
Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesi |
Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to the first request for rescue analgesia in minutes
기간: from end of surgery to the first request for nalbuphine
|
time in minutes to first rescue analgesia will be measured. |
from end of surgery to the first request for nalbuphine
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
postoperative pain assessed as Numerical rating score (NRS)
기간: from 30 minutes after surgery to 24 hours after surgery
|
from 30 minutes after surgery to 24 hours after surgery
|
|
|
motor block using modified bromage scale
기간: from 30 minutes to 24 hours after surgery
|
from 30 minutes to 24 hours after surgery
|
|
|
total nalbuphine consumption in milligram (mg)
기간: from end of surgery to 24 hours after surgery
|
from end of surgery to 24 hours after surgery
|
|
|
heart rate
기간: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
sedation score
기간: from 30 minutes after the end of operations to 24 hours postoperative .
|
using ramsay sedation scale |
from 30 minutes after the end of operations to 24 hours postoperative .
|
|
mean arterial pressure
기간: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
systolic blood pressure
기간: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
diastolic blood pressure
기간: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- MS-228-2026
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .